Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDI Safety Data Guidance Sets Evidence Bar Too High, Attorney Says

This article was originally published in The Tan Sheet

Executive Summary

The new dietary ingredient notification draft guidance sets a higher standard for evidence needed to support NDI notifications, similar to that required for food additives approvals, a food and drug attorney says.

You may also be interested in...



FDA Should Accept Industry’s Grandfathered Ingredient Lists – NPA

FDA Should Accept Industry’s Grandfathered Ingredient Lists – NPA

Trade Groups Dismiss Jarrow’s Criticism Of FDA’s Fabricant

Dietary supplement industry trade groups disavow statements by Jarrow Formulas’ president that cast as industry consensus his criticism of Daniel Fabricant’s work as FDA’s top supplement program official.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel